Atsena Therapeutics

Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases using proprietary AAV technology platforms. The company's pipeline includes ATSN-201 in Phase 3 trials for X-linked retinoschisis, ATSN-101 for Leber Congenital Amaurosis 1, and earlier-stage programs for Usher Syndrome 1B and Stargardt disease.